Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer.

Overman, M J; Adam, L; Raghav, K; Wang, J; Kee, B; Fogelman, D; Eng, C; Vilar, E; Shroff, R; Dasari, A; Wolff, R; Morris, J; Karunasena, E; Pisanic, T R; Azad, N; Kopetz, S

Overman, M J; Adam, L; Raghav, K; Wang, J; Kee, B; Fogelman, D; Eng, C; Vilar, E; Shroff, R; Dasari, A; Wolff, R; Morris, J; Karunasena, E; Pisanic, T R; Azad, N; Kopetz, S.

Ann Oncol ; 30(3): 495, 2019 03 01.

Article in En | MEDLINE | ID: mdl-29982323

Fulltext

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6442652
https://dx.doi.org/10.1093/annonc/mdy221

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Ann Oncol Year: 2019 Document type: Article

Fulltext

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6442652
https://dx.doi.org/10.1093/annonc/mdy221

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Ann Oncol Year: 2019 Document type: Article